Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling

In a recent paper in Nature, Park et al. propose a mechanism through which intestinal dysbiosis compromises the efficacy of immunotherapy targeting the PD-L1/PD−1 interaction. Dysbiosis may upregulate a pair of checkpoint molecules, i.e. PD-L2 interacting with RGMb. Antibodies targeting PD-L2/RGMb c...

Descripción completa

Detalles Bibliográficos
Autores principales: Fidelle, Marine, Lebhar, Isabelle, Zitvogel, Laurence, Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308862/
https://www.ncbi.nlm.nih.gov/pubmed/37396957
http://dx.doi.org/10.1080/2162402X.2023.2224679
_version_ 1785066337095122944
author Fidelle, Marine
Lebhar, Isabelle
Zitvogel, Laurence
Kroemer, Guido
author_facet Fidelle, Marine
Lebhar, Isabelle
Zitvogel, Laurence
Kroemer, Guido
author_sort Fidelle, Marine
collection PubMed
description In a recent paper in Nature, Park et al. propose a mechanism through which intestinal dysbiosis compromises the efficacy of immunotherapy targeting the PD-L1/PD−1 interaction. Dysbiosis may upregulate a pair of checkpoint molecules, i.e. PD-L2 interacting with RGMb. Antibodies targeting PD-L2/RGMb can restore responses to PD−1 blockade in the context of dysbiosis.
format Online
Article
Text
id pubmed-10308862
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-103088622023-06-30 Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling Fidelle, Marine Lebhar, Isabelle Zitvogel, Laurence Kroemer, Guido Oncoimmunology Editorial In a recent paper in Nature, Park et al. propose a mechanism through which intestinal dysbiosis compromises the efficacy of immunotherapy targeting the PD-L1/PD−1 interaction. Dysbiosis may upregulate a pair of checkpoint molecules, i.e. PD-L2 interacting with RGMb. Antibodies targeting PD-L2/RGMb can restore responses to PD−1 blockade in the context of dysbiosis. Taylor & Francis 2023-06-28 /pmc/articles/PMC10308862/ /pubmed/37396957 http://dx.doi.org/10.1080/2162402X.2023.2224679 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Editorial
Fidelle, Marine
Lebhar, Isabelle
Zitvogel, Laurence
Kroemer, Guido
Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling
title Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling
title_full Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling
title_fullStr Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling
title_full_unstemmed Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling
title_short Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling
title_sort microbiota-associated immunotherapy resistance caused by deficient pd-l2 - rgmb signaling
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308862/
https://www.ncbi.nlm.nih.gov/pubmed/37396957
http://dx.doi.org/10.1080/2162402X.2023.2224679
work_keys_str_mv AT fidellemarine microbiotaassociatedimmunotherapyresistancecausedbydeficientpdl2rgmbsignaling
AT lebharisabelle microbiotaassociatedimmunotherapyresistancecausedbydeficientpdl2rgmbsignaling
AT zitvogellaurence microbiotaassociatedimmunotherapyresistancecausedbydeficientpdl2rgmbsignaling
AT kroemerguido microbiotaassociatedimmunotherapyresistancecausedbydeficientpdl2rgmbsignaling

Ejemplares similares